Perjeta® (pertuzumab) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	Email:	

Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured: _____

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured: _____

Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:	Last Name: *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.				
Address:	City:	State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:	Office Contact Name:	Phone:			

Specialty *(Check one):* ☐ **Oncologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
Address: _____
☐ Administration code(s) (CPT): _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other _____
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for: ☐ **Perjeta (pertuzumab) Dose:** _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (clinical documentation required):
What is the human epidermal growth factor receptor 2 (HER2) status? ☐ HER2 positive ☐ HER2 negative ☐ Unknown

☐ **Biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer**
Please indicate the clinical setting in which the requested drug will be used: ☐ Unresectable gross residual (R2) disease
☐ Resected gross residual (R2) disease ☐ Metastatic disease ☐ Other
Please indicate the place in therapy in which the requested drug will be used: ☐ First-line treatment ☐ Subsequent treatment
☐ Yes ☐ No Will the requested drug be used in combination with trastuzumab?

☐ **Breast cancer**
Please select the clinical setting in which the requested drug will be used:
☐ Adjuvant therapy
→ ☐ Yes ☐ No Is the patient's disease node-positive or at high-risk for recurrence?
☐ Yes ☐ No Will the requested drug be used in combination with trastuzumab and chemotherapy?
How many months has the patient received therapy with the requested medication? _____
☐ Neoadjuvant (pre-operative) therapy
→ ☐ Yes ☐ No Is the disease locally advanced, inflammatory, or early stage (either greater than 2 cm in diameter or node positive)?
☐ Yes ☐ No Will the requested drug be used in combination with trastuzumab and chemotherapy?
How many months has the patient received therapy with the requested medication? _____

Continued on next page

Perjeta® (pertuzumab) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ Treatment of recurrent, metastatic disease or the disease had no response to preoperative systemic therapy
→ What is the clinical setting in which the requested drug will be used? ☐ Metastatic disease ☐ Recurrent disease
☐ The disease had no response to preoperative systemic therapy
☐ Yes ☐ No Will the requested drug be used in combination with trastuzumab with or without chemotherapy?
☐ Other

☐ **Colorectal cancer (Including appendiceal adenocarcinoma and anal adenocarcinoma)**
☐ Yes ☐ No ☐ Unknown Does the patient have human epidermal growth factor receptor 2 (HER2)- amplified disease?
☐ Yes ☐ No ☐ Unknown Does the patient have RAS and BRAF wild-type disease?
☐ Yes ☐ No Has the patient previously been treated with a HER2 inhibitor?
☐ Yes ☐ No Will the requested drug be used in combination with trastuzumab?
☐ Yes ☐ No Will the requested drug be used as subsequent therapy for progression of advanced or metastatic disease?
→ ☐ Yes ☐ No Is the patient appropriate for intensive therapy?

☐ **Salivary gland tumor**
Please indicate the clinical setting in which the requested drug will be used: ☐ Recurrent disease ☐ Unresectable disease
☐ Metastatic disease ☐ Other
☐ Yes ☐ No Will the requested drug be used in combination with trastuzumab?

For Continuation Requests (clinical documentation required):
☐ Yes ☐ No Is there evidence of disease progression or unacceptable toxicity while on the current regimen?
☐ Yes ☐ No Is the requested drug being used as adjuvant or neoadjuvant treatment of breast cancer?
→ How many months of the requested medication has the patient received? _____

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required)*: _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.